Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This is an open -label randomized phase II study of dose-dense
Fluorouracil/Epirubicin/Cyclophosphamide (FEC) administered with Epirubicin of 75mg/m2
(FEC75) and Epirubicin 90mg/m2 (FEC90) in untreated patients with early breast cancer.